$322 Million is the total value of JOHNSON & JOHNSON's 22 reported holdings in Q2 2023. The portfolio turnover from Q1 2023 to Q2 2023 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| PTGX | Protagonist Therapeutics Inc. | $67,646,434 | +20.1% | 2,449,183 | 0.0% | 21.00% | +14.6% | |
| CVRX | CVRx, Inc. | $53,971,678 | +65.7% | 3,495,575 | 0.0% | 16.76% | +58.1% | |
| MGTX | MeiraGTx Holdings plc | $44,627,950 | +30.0% | 6,641,064 | 0.0% | 13.86% | +24.1% | |
| XNCR | Xencor, Inc. | $18,679,108 | -10.5% | 748,062 | 0.0% | 5.80% | -14.5% | |
| FUSN | Fusion Pharmaceuticals Inc. | $17,141,310 | +23.9% | 3,670,516 | 0.0% | 5.32% | +18.2% | |
| FATE | Fate Therapeutics, Inc. | $16,084,345 | -16.5% | 3,379,064 | 0.0% | 4.99% | -20.3% | |
| Procept BioRobotics Corporation | $12,653,144 | +24.5% | 357,939 | 0.0% | 3.93% | +18.8% | ||
| PNT | Point Biopharma Global Inc. | $9,060,000 | +24.6% | 1,000,000 | 0.0% | 2.81% | +18.9% | |
| ARWR | Arrowhead Pharmaceuticals, Inc. | $8,829,345 | +40.4% | 247,598 | 0.0% | 2.74% | +34.0% | |
| NNOX | Nano-X Imaging Ltd. | $4,921,235 | +168.5% | 317,704 | 0.0% | 1.53% | +156.4% | |
| VOR | Vor Biopharma, Inc. | $3,320,693 | -42.6% | 1,074,658 | 0.0% | 1.03% | -45.2% | |
| ALDX | Aldeyra Therapeutics, Inc. | $3,312,657 | -15.5% | 394,834 | 0.0% | 1.03% | -19.3% | |
| Cue Health, Inc. | $2,047,531 | -79.7% | 5,548,864 | 0.0% | 0.64% | -80.6% | ||
| ACET | Adicet Bio, Inc. | $1,771,334 | -57.8% | 728,944 | 0.0% | 0.55% | -59.7% | |
| PHGE | BiomX Inc. | $768,025 | +18.0% | 2,133,402 | 0.0% | 0.24% | +12.3% | |
| SomaLogic, Inc. | $649,230 | -9.4% | 281,052 | 0.0% | 0.20% | -13.3% | ||
| CLSD | Clearside Biomedical, Inc. | $189,984 | +7.7% | 169,629 | 0.0% | 0.06% | +3.5% | |
| Apollomics, Inc. | $75,934 | -76.3% | 13,252 | 0.0% | 0.02% | -76.9% | ||
| SENS | Senseonics Holdings, Inc. | $41,681 | +7.5% | 54,621 | 0.0% | 0.01% | 0.0% | |
| TCON | Tracon Pharmaceuticals, Inc. | $24,445 | -84.6% | 84,003 | 0.0% | 0.01% | -84.6% | |
| CBIO | Catalyst Biosciences, Inc. | $23,540 | +69.9% | 66,951 | 0.0% | 0.01% | +40.0% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-08-02
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| LEGEND BIOTECH CORPORATION | 9 | Q3 2023 | 25.6% |
| FATE THERAPEUTICS, INC. | 9 | Q3 2023 | 24.8% |
| PROTAGONIST THERAPEUTICS INC. | 9 | Q3 2023 | 21.0% |
| CVRX, INC. | 9 | Q3 2023 | 19.5% |
| MEIRAGTX HOLDINGS PLC | 9 | Q3 2023 | 13.9% |
| Arrowhead Pharmaceuticals, Inc. | 9 | Q3 2023 | 24.6% |
| PROCEPT BIOROBOTICS CORPORATION | 9 | Q3 2023 | 10.5% |
| CUE HEALTH, INC. | 9 | Q3 2023 | 8.5% |
| FUSION PHARMACEUTICALS INC. | 9 | Q3 2023 | 5.4% |
| POINT BIOPHARMA GLOBAL INC. | 9 | Q3 2023 | 2.8% |
View JOHNSON & JOHNSON's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Fusion Pharmaceuticals Inc. | January 27, 2023 | 3,670,516 | 8.2% |
| Protagonist Therapeutics, Inc | January 11, 2023 | 2,449,183 | 5.0% |
| MeiraGTx Holdings plc | November 14, 2022 | 6,641,064 | 13.7% |
| PhaseBio Pharmaceuticals Inc | February 01, 2022 | 1,607,044 | 3.3% |
| Provention Bio, Inc. | January 17, 2020 | 1,124,973 | 2.4% |
| ADURO BIOTECH, INC. | January 22, 2019 | 3,906,207 | 4.9% |
| Aldeyra Therapeutics, Inc. | January 22, 2019 | 1,050,292 | 4.0% |
| GI DYNAMICS, INC. | January 22, 2019 | 565,569 | 3.7% |
| MACROGENICS INC | January 22, 2019 | 1,923,077 | 4.6% |
| Merus N.V. | January 22, 2019 | ? | ? |
View JOHNSON & JOHNSON's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| CERT | 2024-05-21 |
| 25-NSE | 2024-05-20 |
| 8-A12B | 2024-05-20 |
| 8-K | 2024-05-20 |
| SC 13G/A | 2024-05-20 |
| 8-K | 2024-05-17 |
| 424B2 | 2024-05-16 |
| 424B2 | 2024-05-15 |
| 424B5 | 2024-05-14 |
| FWP | 2024-05-14 |
View JOHNSON & JOHNSON's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Annual reports (10-K)
- Quarterly reports (10-Q)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.